Back to Ovarian Cancer
NCT03229122
NCT03229122
Who may be able to join
Who might be able to join this trial:
- You are willing and able to sign a consent form agreeing to take part in the study
- You are a Japanese woman aged 20 or older
- You have been newly diagnosed with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, and this diagnosis has been confirmed by examining tissue removed during surgery (not just from a fluid sample)
- Your tissue sample can be sent to a central lab for review
- You gave your written consent to join within 60 days of your cancer diagnosis
Who may not be able to join:
- You have a serious ongoing physical illness (other than cancer) or a severe mental health condition that your doctor believes could increase your risk of harm or affect the study results
- Your doctor decides for any reason that joining this trial would not be appropriate for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
26 December 2016
Est. completion
6 July 2018
Where this trial is recruiting
🇯🇵 Japan
Primary endpoints
Assessment of the ownership ratio of gBRCAm in the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer in Japan.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.